Catalog No. |
TD-VK565086 |
Species reactivity |
SARS-CoV-2 (2019-nCoV) |
Applications |
Research Grade Biosimilar |
Host species |
Human |
Isotype |
IgG1, kappa |
Expression system |
Mammalian Cells |
Clonality |
Monoclonal |
Target |
Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2 |
Endotoxin level |
Please contact the lab for this information. |
Purity |
>95% purity as determined by SDS-PAGE. |
Purification |
Protein A/G, purified from cell culture supernatant. |
Accession |
P0DTC2 |
Form |
Liquid |
Storage buffer |
0.01M PBS,pH7.4. |
Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
Alternate Names |
AZD8895,COV2-2196,CAS:2420564-02-7 |
Background |
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor. |
Note |
For research use only. Not for use in clinical or therapeutic applications. |